Share This Article:

An open level study to assess the glycemic control effect of metformin and Pioglitazone as add on therapy along with sulfonylurea in uncomplicated type2 diabetes mellitus

Abstract Full-Text HTML Download Download as PDF (Size:145KB) PP. 191-195
DOI: 10.4236/jdm.2012.22030    3,204 Downloads   5,241 Views   Citations

ABSTRACT

Introduction: Management of hyperglycemia in type2 diabetes mellitus (T2DM) becomes the top priority. When single antidiabetic drug is ineffective, combination is required for good glycemic control. There is a dearth of studies that provide head to head comparison of the ability of combinations and therefore need further study. Objectives: To assess and compare the glycemic control and physical parameter altering effect of glibenclamide, glibenclamide & Pioglitazone, glibenclamide & metformin in T2DM. Methods and materials: 100 T2DM patients were selected from outpatients department of medicine following prefixed inclusion and exclusion criteria. Fasting and postprandial blood glucose (fbg & ppbg) and physical parameters (waist, hip and thigh circumference) were measured before and after treatment with study drugs and adverse effects of these drugs were recorded. Data were analyzed by employing paired t-test and chi-square test. Results: 11 patients lost the follow up. A some total of 89 middle aged, predominantly male, non obese T2DM patients after exposure to the study drugs showed significant (p < 0.05) reduction of blood glucose from baseline. Reduction of blood glucose and waist: hip ratio were observed significantly (p < 0.05) more with glibenclamide and metformin combination with some tolerable side effects. Discussion: Metformin and Pioglitazone both are insulin sensitizer but metformin & glibenclamide combination showed significantly (p < 0.001) more reduction of fbg, ppbg and central obesity (waist: hip ratio) than Pioglitazone & glibenclamide combination. Therefore Judicious use of low dose of glibenclamide and full dose of metformin become safe, effective and cheap for the treatment of type 2 diabetes patients in poor country like India.

Conflicts of Interest

The authors declare no conflicts of interest.

Cite this paper

Mazumdar, G. , Swaika, B. and Dasgupta, A. (2012) An open level study to assess the glycemic control effect of metformin and Pioglitazone as add on therapy along with sulfonylurea in uncomplicated type2 diabetes mellitus. Journal of Diabetes Mellitus, 2, 191-195. doi: 10.4236/jdm.2012.22030.

References

[1] Zimmet, P., Alberti, K.G. and Shaw, J. (2001) Global and social implication of the diabetes epidemic. Nature, 414, 782-787. doi:10.1038/414782a
[2] American Diabetes Association. (2008) Standards of medical care in diabetes. Diabetes Care, 31, S12-S54. doi:10.2337/dc08-S012
[3] Task Force Members. (2007) Guidelines on diabetes, prediabetes and cardiovascular diseases: Executive summary. The task force on diabetes and cardiovascular diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD) European Heart Journal, 28, 88-136
[4] UK Prospective Diabetes Study (UKPDS) Group. (1998) Intensive blood glucose control with sulfonylurea or insulin compared with conventional treatment and risk of complication in patients with type 2 diabetes (UKPDS 33). The Lancet, 352, 837-853. doi:10.1016/S0140-6736(98)07019-6
[5] Gaede, P., et al. (2008) Effect of a multifactorial intervention on mortality of type 2 diabetes. The New England Journal of Medicine, 358, 580-591. doi:10.1056/NEJMoa0706245
[6] White, J.R. and Campbell, R.K. (2009) Overview of medications used to treat type 2 diabetes. In: White, J.R. and Campbell, R.K., Eds., ADA/PDR Medication for the Treatment of Diabetes, The Healthcare business of Thomson Reuters, Montvale, 5-15.
[7] Nathan, D.M., Buse, J.B., Davidson, M.B., et al. (2006) Management of hyperglycemia in type 2 diabetes mellitus: A consensus algorithm for the initiation and adjustment of therapy. In: White, J.R. and Campbell, R.K., Eds., ADA/PDR Medication for the Treatment of Diabetes, The Healthcare business of Thomson Reuters, Montvale, 17-31.
[8] Warram, J.H., Martin, B.C., et al. (1990) Slow glucose removal rate and hyperinsulinemia precede the development of type 2 diabetes in the offspring of diabetic parents. Annals of International Medicine, 113, 909-915.
[9] Lebovitz, H.E. (2002) Rational for and role of thiazolidinediones in type 2 diabetes mellitus. The American Journal of cardiology, 90, 34-41. doi:10.1016/S0002-9149(02)02557-2
[10] Bailey, C.J. (2009) Metformin. In: Lebovitz, H.E., Ed., Therapy for Diabetes Mellitus and Related Disorders, 5th Edition, American Diabetes Association, Alexandria, 235-253.
[11] Lebovitz, H.E. (2009) Thiazolidinedione. In: Lebovitz, H.E., Ed., Therapy for Diabetes Mellitus and Related Disorders, 5th Edition, American Diabetes Association, Alexandria, 260-272.
[12] Buse, J.B., Polonsky, K.S. and Burant, C.F. () Type 2 diabetes mellitus. In: Kronenberg, H.M., Melmed, S., Polanski, K.S., Larsen, P.R., Eds., William’s Textbook of Endocrinology, 11th Edition, Saunders, Philadelphia, 1330-1389.
[13] Klezig, H., kober, G., Matter, C., et al. (1999) Sulfonylurea and ischemic preconditioning; a double blind placebo controlled evaluation of glimepiride and glibenclamide. European Heart Journal, 20, 439-446. doi:10.1053/euhj.1998.1242
[14] Riddle, M.C. (2003) Editorial sulfonylureas differ in effects on ischemic preconditioning—Is it time to retire glyburide? The Journal of Clinical Endocrinology Metabolism, 88, 528-530. doi:10.1210/jc.2002-021971
[15] Lebovitz, H.E. (2010) Management of hyperglycemia with oral antihyperglycemic agents in type 2 diabetes. In: Khan, C.R., Weir, G.C., King, G.L., Jacobson, A.M., Moses, A.C., Smith, R.J. Eds., Joslin’s Diabetes Mellitus, 14th Edition, Wolters Kluwer Pvt Ltd., New Delhi, 685-710.
[16] UK Prospective Diabetes Study (UKPDS) Group (2005) Association of glycemia with micro vascular and macro vascular complications of type 2 diabetes (UKPDS 35): Prospective observational study. British Medical Journal, 32, 405-412.
[17] Vague, P. and Moulin, J.P. (1982) The defective glucose sensitivity of the β-cell in noninsulin dependent diabetes: Improvement after twenty hours normoglycemia. Metabolism, 31, 139-142. doi:10.1016/0026-0495(82)90125-1
[18] Nathan, D.M. (2010) Relationship between metabolic control and long-term complications of diabetes. In: Khan, C.R., Weir, G.C., King, G.L., Jacobson, A.M., Moses, A.C., Smith, R.J. Eds., Joslin’s Diabetes Mellitus, 14th Edition, New Delhi, Wolters Kluwer Pvt Ltd., 809-821.
[19] Rothman, D.L., Magnusson, I., Katz, L.D., et al. (1991) Quantitation of hepatic glycogenolysis and gluconeogenesis in fasting human with 13C NMR. Science, 254, 573-576.
[20] Long, Y.C. and Zierath, J.R. (2006) AMP-activated protein kinase signaling in metabolic regulation. The Journal of Clinical Investigation, 16, 1776-1783. doi:10.1172/JCI29044

  
comments powered by Disqus

Copyright © 2019 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.